Investigation Launched Following EyePoint’s Failed Clinical Trial Results
News provided byEyePoint, Inc · 2 min read
RADNOR, Pa., Sept. 6, 2026 /CourierPR/ -- Investigating Potential Securities Law Violations Following Disappointing Clinical Trial Results for EyePoint, Inc.
Investors in EyePoint, Inc. (NASDAQ: EYPT) are urged to contact Kessler Topaz Meltzer & Check, LLP, a leading securities litigation law firm, as the firm is investigating possible violations of federal securities laws. This alert comes in the wake of the company's announcement of negative Phase 3 clinical trial results.
On August 17, 2026, EyePoint issued a press release reporting topline results from the LUGANO trial, the first pivotal Phase 3 clinical trial for DURAVYU™ (vorolanib intravitreal insert), which was intended to treat wet age-related macular degeneration (wet AMD). The company disclosed that DURAVYU failed to meet the prespecified primary endpoint, change in best-corrected visual acuity compared to on-label aflibercept, in the full dataset of the Phase 3 LUGANO trial.
The announcement sent a shockwave through the market, causing EyePoint’s stock price to plummet by over 66%. This significant drop in share value has left many investors questioning the company’s future and the efficacy of its product.
The potential legal ramifications for EyePoint, Inc. have not gone unnoticed. Kessler Topaz Meltzer & Check, LLP, which has a history of representing investors in securities fraud cases, is currently investigating the company. The firm advises investors who purchased or acquired EyePoint securities and have experienced financial losses to contact them for a free legal consultation.
“Investors who have lost money on their EyePoint investment due to the company’s poor performance or misrepresentations should consider seeking legal advice,” said Jonathan Naji, an attorney with Kessler Topaz Meltzer & Check, LLP.
For those who wish to learn more about their legal rights, Kessler Topaz Meltzer & Check, LLP, has set up a dedicated webpage: <https://www.ktmc.com/eypt-eyepoint-inc-investigation?utm_campaign=hc&utm_source=PR_Newswire&utm_medium=pressrelease&utm_campaign=eypt&mktm=PR>. The firm assures that there is no cost or obligation to speak with an attorney.
Kessler Topaz Meltzer & Check, LLP, is a well-established law firm with a strong track record in securities litigation. The firm, based in Pennsylvania and California, has represented numerous investors and has achieved significant recoveries. According to the firm, it has recovered over $25 billion for its clients and the classes they represent.
The firm’s expertise extends beyond individual investors; they also represent major pension funds, asset managers, and international investors. Kessler Topaz Meltzer & Check, LLP, has been recognized by various legal publications and organizations, including Chambers & Partners USA 2026, The National Law Journal’s Plaintiff’s Hot List and Trailblazers in Plaintiffs’ Law, and Lawdragon’s Class Action Firm of the Year.
Investors are urged to stay vigilant and seek legal counsel if they believe they have been affected by any potential securities law violations.